

Supplementary Table 4. Frequency (%) of the 25 severe adverse events after COVID-19 vaccination stratified by age groups

Severe AEs	Total	18–24 yr	25–39 yr	40–49 yr	50–64 yr	65–74 yr	≥75 yr
Total							
T2DM	6,829	18	377	893	2,811	1,852	878
Non-diabetic	20,487	54	1,131	2,679	8,433	5,556	2,634
Ischemic stroke							
T2DM	28 (0.4)	0	1 (0.3)	3 (0.3)	7 (0.2)	11 (0.6)	6 (0.7)
Non-diabetic	30 (0.1)	0	3 (0.3)	0	5 (0.1)	12 (0.2)	10 (0.4)
Thrombocytopenia							
T2DM	20 (0.3)	0	0	1 (0.1)	9 (0.3)	7 (0.4)	3 (0.3)
Non-diabetic	27 (0.1)	0	2 (0.2)	1 (0.0)	8 (0.1)	10 (0.2)	6 (0.2)
Bell's palsy							
T2DM	115 (1.7)	1 (5.6)	3 (0.8)	17 (1.9)	48 (1.7)	32 (1.7)	14 (1.6)
Non-diabetic	86 (0.4)	0	0	1 (0.0)	45 (0.5)	31 (0.6)	9 (0.3)
Deep vein thrombosis							
T2DM	45 (0.7)	0	0	4 (0.4)	19 (0.7)	17 (0.9)	5 (0.6)
Non-diabetic	44 (0.2)	0	0	1 (0.0)	17 (0.2)	19 (0.3)	7 (0.3)
Pulmonary embolism							
T2DM	55 (0.8)	0	2 (0.5)	5 (0.6)	18 (0.6)	21 (1.1)	9 (1.0)
Non-diabetic	77 (0.4)	0	9 (0.8)	4 (0.1)	27 (0.3)	24 (0.4)	13 (0.5)
Lymphadenopathy							
T2DM	199 (2.9)	0	14 (3.7)	50 (5.6)	93 (3.3)	33 (1.8)	9 (1.0)
Non-diabetic	310 (1.5)	1 (1.9)	17 (1.5)	73 (2.7)	167 (2.0)	42 (0.8)	10 (0.4)

Values are presented as number (%).

COVID-19, coronavirus disease 2019; T2DM, type 2 diabetes mellitus.